RxDoctor Payments DataLook up a doctor →

Yong Park, MD

Neurology with Special Qualifications in Child Neurology · Augusta, GANPI 1760582712

Payments from drug & device makers

$393,086in general payments, 2019–2025

Across 734 payments — averaging $535.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB SA$174K
  • Jazz Pharmaceuticals Inc.$87K
  • SK Life Science, Inc.$54K
  • Greenwich Biosciences, Inc.$39K
  • GW Research Limited$18K
  • Eisai Inc.$11K
  • plus $10K from 45 others

What the payments were for

  • Consulting fees$5001%
  • Speaking & faculty fees$55,90472%
  • Travel & lodging$6,4538%
  • Food & beverage$14,96519%
  • Education$620%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$393,086 in reported general payments places this provider in the 85th percentile of 41 neurology with special qualifications in child neurology providers in Georgia.

See all neurology with special qualifications in child neurology providers in Georgia

Medicare billing

Part B allowed, 2024
$5,041
Medicare patients
54
Services billed
67

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EpidiolexCannabidiol (Cbd)44$303,859
XcopriCenobamate30$32,950
FycompaPerampanel27$23,813
NayzilamMidazolam28$22,301
TopamaxTopiramate12$18,831
KeppraLevetiracetam12$11,976
Oxcarbazepine54$10,450
Clobazam31$3,212
Lacosamide32$2,822
Levetiracetam56$2,544
Felbamate11$2,038
Lamotrigine33$466
Topiramate31$253
Clonazepam11$92
Lorazepam18$88

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
SK Life Science, Inc.Xcopri$54,340$32,95030 claims
Eisai Inc.Fycompa$11,317$23,81327 claims
UCB, Inc.Nayzilam$2,341$22,30128 claims
UCB SAKeppra$173,826$11,97612 claims
Upsher-smith Laboratories LLCTopiramate$55$25331 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 41 neurology with special qualifications in child neurology providers in Georgia.

Other neurology with special qualifications in child neurology in Augusta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →